A western blot analysis on treated SK-BR-3 showed that GO treatment led to a significant reduction in overall HER-2 levels, accompanied by down regulation of expression and activation of HER-2-driven signalling pathways such as phosphatidylinositol-3-kinase (PI3K)/proteinkinase B (AKT) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways, which mediate cancer cell survival and proliferation. Here, ERBB2 is linked to cancer.